BRPI1007945C8 - formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral - Google Patents

formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral

Info

Publication number
BRPI1007945C8
BRPI1007945C8 BRPI1007945A BRPI1007945A BRPI1007945C8 BR PI1007945 C8 BRPI1007945 C8 BR PI1007945C8 BR PI1007945 A BRPI1007945 A BR PI1007945A BR PI1007945 A BRPI1007945 A BR PI1007945A BR PI1007945 C8 BRPI1007945 C8 BR PI1007945C8
Authority
BR
Brazil
Prior art keywords
nitazoxanide
controlled release
tizoxanide
combination
oral administration
Prior art date
Application number
BRPI1007945A
Other languages
English (en)
Inventor
Rossignol Jean-François
Ayers Marc
Original Assignee
Romark Laboratories Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romark Laboratories Lc filed Critical Romark Laboratories Lc
Publication of BRPI1007945A2 publication Critical patent/BRPI1007945A2/pt
Publication of BRPI1007945B1 publication Critical patent/BRPI1007945B1/pt
Publication of BRPI1007945B8 publication Critical patent/BRPI1007945B8/pt
Publication of BRPI1007945C1 publication Critical patent/BRPI1007945C1/pt
Publication of BRPI1007945C8 publication Critical patent/BRPI1007945C8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

composição farmacêutica,com´primido, e, usos de nitazoxanida ou de um seu análogo. são fornecidos formulações de dosagem sólidas de nitazoxanida ou um análogo de nitazoxanida que compreendem uma porção de liberação controlada e uma porção de liberação imediata. a composição farmacêutica está tipicamente na forma de uma dosagem oral sólida de bicamada compreendendo (a) uma primeira camada compreendendo uma primeira quantidade de nitazoxanida ou de seu análogo em uma formulação de liberação controlada, e (b) uma segunda quantidade de nitazoxanida ou de seu análogo em uma formulação de liberação imediata. também é fornecido método de uso das formulações no tratamento de hepatite c.
BRPI1007945A 2009-02-13 2010-02-12 formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral BRPI1007945C8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20228509P 2009-02-13 2009-02-13
US61/202285 2009-02-13
PCT/US2010/024000 WO2010093854A1 (en) 2009-02-13 2010-02-12 Controlled release pharmaceutical formulations of nitazoxanide

Publications (5)

Publication Number Publication Date
BRPI1007945A2 BRPI1007945A2 (pt) 2015-09-01
BRPI1007945B1 BRPI1007945B1 (pt) 2020-08-04
BRPI1007945B8 BRPI1007945B8 (pt) 2020-08-18
BRPI1007945C1 BRPI1007945C1 (pt) 2020-09-01
BRPI1007945C8 true BRPI1007945C8 (pt) 2021-05-25

Family

ID=42560126

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007945A BRPI1007945C8 (pt) 2009-02-13 2010-02-12 formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral

Country Status (23)

Country Link
US (5) US8524278B2 (pt)
EP (1) EP2395840B1 (pt)
JP (3) JP5726766B2 (pt)
KR (1) KR101697800B1 (pt)
CN (2) CN102395276A (pt)
AU (3) AU2010213678B2 (pt)
BR (1) BRPI1007945C8 (pt)
CA (1) CA2752233C (pt)
CO (1) CO6501159A2 (pt)
CY (1) CY1123162T1 (pt)
DK (1) DK2395840T3 (pt)
EA (1) EA029018B1 (pt)
ES (1) ES2797493T3 (pt)
HR (1) HRP20201055T1 (pt)
HU (1) HUE049501T2 (pt)
IL (1) IL214624A0 (pt)
LT (1) LT2395840T (pt)
MX (2) MX381895B (pt)
PL (1) PL2395840T3 (pt)
PT (1) PT2395840T (pt)
SI (1) SI2395840T1 (pt)
UA (1) UA107564C2 (pt)
WO (1) WO2010093854A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2907A (en) * 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
EP2395840B1 (en) * 2009-02-13 2020-04-15 Romark Laboratories, L.C. Controlled release pharmaceutical formulations of nitazoxanide
WO2013110975A1 (es) 2012-01-27 2013-08-01 Siegfried Rhein S.A. De C.V. Composición de nitazoxanida mejorada y proceso para prepararla
WO2013124768A1 (en) * 2012-02-20 2013-08-29 Lupin Limited Bilayer tablet of dronedarone
KR101639692B1 (ko) * 2013-12-13 2016-07-14 제일약품주식회사 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
EP3217795A4 (en) 2014-11-11 2018-08-22 Romark Laboratories, L.C. Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
MX381896B (es) 2016-03-31 2025-03-13 Romark Laboratories Lc Compuestos de tiazolida para el tratamiento de infecciones virales.
US10905680B2 (en) * 2016-04-11 2021-02-02 Genfit Methods of treatment for cholestatic and fibrotic diseases
JP7134092B2 (ja) * 2016-04-11 2022-09-09 ジェンフィ 胆汁うっ滞性及び線維性の疾患の処置方法
KR102636273B1 (ko) * 2017-03-08 2024-02-16 신알엑스 파마, 엘엘씨 플로로글루시놀 및 트리메틸플로로글루시놀의 제약 제제
BR112019018162A2 (pt) * 2017-03-13 2020-04-07 Genfit Composições farmacêuticas para terapia de combinação
WO2018195035A1 (en) 2017-04-18 2018-10-25 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase a3
EP3639855A4 (en) * 2017-06-16 2021-03-17 The Doshisha COMPOUNDS HAVING CASPASE INHIBITORING ACTIVITY, PHARMACEUTICAL AGENT CONTAINING THEM FOR THE TREATMENT OR PREVENTION OF SYMPTOMS, DISORDERS OR DISEASES OF CORNEAL ENDOTHELIUM, AND APPLICATION OF SUCH PHARMACEUTICAL AGENT
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
CN108524460B (zh) * 2018-05-14 2021-01-01 佛山市南海东方澳龙制药有限公司 烯啶虫胺双层片
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
CN110025621A (zh) * 2019-03-13 2019-07-19 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 替唑尼特和硝唑尼特在制备抗炎药物中的应用
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
CN114845704A (zh) * 2019-12-19 2022-08-02 赛特瑞恩股份有限公司 包含西苯唑啉或其盐的药物制剂
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩
WO2022046622A1 (en) 2020-08-24 2022-03-03 Romark Laboratories L.C. Use of thiazolides against coronaviruses
WO2022130406A1 (en) * 2020-12-15 2022-06-23 Cipla Limited Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease
WO2023058046A1 (en) 2021-10-05 2023-04-13 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) An improved process for the preparation of nitazoxanide and intermediates thereof
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5968961A (en) * 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) * 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
KR100426657B1 (ko) * 1997-05-07 2004-04-13 로마크 레버러토리즈, 엘.씨. 티족사나이드 및 니타족사나이드의 약제학적 조성물
US5948440A (en) 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
DK1126826T6 (en) 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
JP4637338B2 (ja) 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
JP5049450B2 (ja) 2000-09-29 2012-10-17 アボツト・ヘルスケア・プロダクツ・ベー・ブイ イオン強度に依存しない徐放性製薬組成物
US7074417B2 (en) 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
BR0213079A (pt) 2001-09-28 2004-11-09 Sun Pharmaceutical Ind Ltd Forma de dosagem para o tratamento da diabetes mellitus
WO2003026626A2 (en) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Modified release dosage forms
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
TW200517127A (en) 2003-08-07 2005-06-01 Sb Pharmco Inc Novel composition
GB0319874D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Novel formulation
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
EP1871365A2 (en) * 2005-04-12 2008-01-02 Romark Laboratories, L.C. Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
AP2907A (en) * 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
JP2006335771A (ja) * 2006-09-22 2006-12-14 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
US20080286344A1 (en) * 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
ES2550755T3 (es) 2007-08-03 2015-11-12 Romark Laboratories, L.C. Compuestos de tiazolida sustituidos con alquilsulfonilo
EP2395840B1 (en) * 2009-02-13 2020-04-15 Romark Laboratories, L.C. Controlled release pharmaceutical formulations of nitazoxanide

Also Published As

Publication number Publication date
EA029018B1 (ru) 2018-01-31
US9827227B2 (en) 2017-11-28
JP5726766B2 (ja) 2015-06-03
US9351937B2 (en) 2016-05-31
CN107260695A (zh) 2017-10-20
JP6117845B2 (ja) 2017-04-19
CN102395276A (zh) 2012-03-28
US11426388B2 (en) 2022-08-30
AU2010213678A1 (en) 2011-09-01
SI2395840T1 (sl) 2020-08-31
LT2395840T (lt) 2020-07-10
AU2017203148A1 (en) 2017-06-01
JP6491174B2 (ja) 2019-03-27
US10383855B2 (en) 2019-08-20
JP2015143258A (ja) 2015-08-06
US20100209505A1 (en) 2010-08-19
KR101697800B1 (ko) 2017-01-18
AU2017203148B2 (en) 2018-08-09
ES2797493T3 (es) 2020-12-02
CA2752233A1 (en) 2010-08-19
PL2395840T3 (pl) 2020-09-07
CA2752233C (en) 2017-01-03
US20180085353A1 (en) 2018-03-29
BRPI1007945C1 (pt) 2020-09-01
BRPI1007945B8 (pt) 2020-08-18
EP2395840B1 (en) 2020-04-15
CY1123162T1 (el) 2021-10-29
US20140065215A1 (en) 2014-03-06
UA107564C2 (uk) 2015-01-26
US20190321338A1 (en) 2019-10-24
BRPI1007945B1 (pt) 2020-08-04
MX2011008530A (es) 2011-10-14
HRP20201055T1 (hr) 2020-10-30
WO2010093854A1 (en) 2010-08-19
CO6501159A2 (es) 2012-08-15
AU2016200971A1 (en) 2016-03-03
MX381895B (es) 2025-03-13
US8524278B2 (en) 2013-09-03
DK2395840T3 (da) 2020-06-08
BRPI1007945A2 (pt) 2015-09-01
IL214624A0 (en) 2011-09-27
EA201190127A1 (ru) 2012-03-30
KR20120008024A (ko) 2012-01-25
EP2395840A4 (en) 2013-12-25
US20160243087A1 (en) 2016-08-25
MX348282B (es) 2017-06-05
HUE049501T2 (hu) 2020-09-28
JP2012518002A (ja) 2012-08-09
AU2016200971B2 (en) 2017-02-23
AU2010213678B2 (en) 2015-11-26
JP2017061561A (ja) 2017-03-30
EP2395840A1 (en) 2011-12-21
PT2395840T (pt) 2020-07-06

Similar Documents

Publication Publication Date Title
BRPI1007945C8 (pt) formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
UY32260A (es) Forma de dosificación farmacéutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o diuretico
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
BR112012016330B8 (pt) ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
AR068820A1 (es) Composicion farmaceutica que comprende la combinacion de diversos agentes venotonicos y vasoprotectores para el tratamiento de la insuficiencia venosa cronica y uso
DK1987063T3 (da) Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
BR112012021445B8 (pt) formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade
ECSP088850A (es) Formulación de medicamento líquida
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
BR112013004714A2 (pt) "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2587 DE 04/08/2020 QUANTO AO QUADRO REIVINDICATORIO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2587 DE 04/08/2020.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24D Patent annual fee: restoration after fee payment
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24D Patent annual fee: restoration after fee payment
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24D Patent annual fee: restoration after fee payment
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2813 DE 03-12-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.